|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Inversely, the high frequency of β-catenin mutations could be related to the increased frequency of malignant transformation in hepatocellular carcinoma.
|
23046672 |
2013 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The results show a modest correlation between diffuse glutamine synthetase immunostaining and exon 3 β-catenin mutations in hepatocellular adenoma and hepatocellular carcinoma with discrepancy rates >50% in both hepatocellular adenoma and hepatocellular carcinoma.
|
27469330 |
2016 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CTNNB1 (40%) and TP53 (21%) mutations were mutually exclusive and defined two major groups of HCC characterized by distinct phenotypes.
|
28532995 |
2017 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The activation of the Wnt pathway due to β-catenin gene mutations contributes to the development of a significant subset of HCC.
|
21093092 |
2011 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The polymorphism rs4135385 of CTNNB1 genotype GA was associated with a higher risk for Stage III + IV HCC (modified Union for International Cancer Control) (P = 0.001, OR = 2.238).Genetic polymorphisms in the WNT2 and CTNNB1 genes were closely associated with HCC risk and progression in a Chinese Han population.
|
28328801 |
2017 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
LHGDN |
Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.
|
18313840 |
2008 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Activation of the Wnt signaling pathway is frequently observed in hepatocellular carcinoma (HCC), though mutation of three of its components, CTNNB1, AXIN1, and AXIN2, is observed substantially less often.
|
18592156 |
2008 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The present results indicate that (1) mutation of exon 3 of the beta-catenin gene can lead to beta-catenin accumulation, although other mechanisms of accumulation may also operate in HCC, and (2) beta-catenin accumulation and mutation of the beta-catenin gene are not early events in hepatocarcinogenesis, and may be associated with the malignant progression of HCC.
|
10665646 |
1999 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These results show that, although chronic CAR activation per se induces HCCs carrying β-catenin mutations, it concurrently down-regulates the Wnt/β-catenin pathway in nontumoral liver.
|
30201494 |
2018 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Using in situ hybridization, the signal corresponding to beta-catenin gene exon 3 mRNA was particularly strong in cytoplasm of HCC when compared with those of paracancerous tissues and normal liver tissues.
|
11570580 |
2001 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In contrast, ALDH3A1 was strongly upregulated in a subset of HCCs characterised by activation of the Wnt/ß-catenin pathway and CTNNB1 mutations.
|
24276407 |
2014 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Mutations in <i>TP53</i> and β-catenin genes are the most frequent aberrations in HCC.
|
28067792 |
2017 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that PAP expression designate a subset of low-grade, low-stage HCC with frequent beta-catenin mutation and hence more favorable prognosis, whereas further genetic or epigenetic alterations, such as p53 mutation and REG1A expression, lead to more advanced HCCs.
|
15814635 |
2005 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A β‑catenin mutant and β‑catenin wild‑type HCC models were treated once daily with i) 10 mg/kg sorafenib, ii) 15 mg/kg refametinib (or 25 mg/kg selumetinib), or iii) sorafenib/refametinib.
|
30747223 |
2019 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Frequent mutations of suppressor genes, such as CTNNB1 (34.8%) and TP53 (26.1%), were detected in the HCC tumors.
|
26046304 |
2015 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Functional studies indicated that the WNT pathway activation signature characteristic of S1 tumors was not simply the result of beta-catenin mutation but rather was the result of transforming growth factor-beta activation, thus representing a new mechanism of WNT pathway activation in HCC.
|
19723656 |
2009 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3.
|
9635572 |
1998 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Finally, integrative analysis of HCAs transformed to hepatocellular carcinoma revealed β-catenin mutation as an early alteration and TERT promoter mutations as associated with the last step of the adenoma-carcinoma transition.
|
24735922 |
2014 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In accordance with the immunohistochemical results, CTNNB1 mutations were less frequent in SH-HCC than C-HCC (3.1 vs. 20.8 %, p < 0.048).
|
26311355 |
2015 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We found a point mutation of beta-catenin in one of nine HCCs in human and a deletion of it in Hep G2 cell line.
|
10811985 |
2000 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CTNNB1 mutations were similarly observed in K19<sup>+</sup> and K19<sup>-</sup> HCC (23% and 19%, respectively), but rare in S-iCCA (3%).
|
31017316 |
2019 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Gene alterations in TERT promoter, TP53, CTNNB1, and HBV integration were closely associated with HCC development, and mutations in TERT promoter are related to poor prognosis.
|
26553052 |
2016 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
WES of the HCC tissue uncovered somatic driver mutations in the beta-catenin (CTNNB1) and nuclear-factor-erythroid-2-related-factor-2 (NFE2L2) genes.
|
25016225 |
2014 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
By contrast, a mutation in the beta-catenin gene in around 22% of HCCs is more rare in HBV-associated tumors.
|
12095925 |
2002 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Our study demonstrates the importance of CTNNB1 mutations and NFE2L2-KEAP1 pathway activation in HB development and defines loss of genomic stability and TERT promoter mutations as prominent characteristics of aggressive HB with HCC features.
|
25135868 |
2014 |